Cozen O’Connor has hired Jeffrey Gendzwill and Keith Fredlake from Kilpatrick Townsend & Stockton into the firm’s Washington, DC office.
The final version of guidelines issued by Canada’s federal drug price regulator last week has caused uproar among the pharma industry.
The English High Court has lifted a stay on Amgen’s lawsuit which accused Sanofi-Aventis and Regeneron of infringing a patent covering pharmaceuticals which treat elevated cholesterol levels.
Swiss pharmaceutical company Roche will pay $350 million for the rights to develop and distribute an investigational COVID-19 antiviral outside of the US.
US biotechnology company Seagen has accused Japanese pharmaceutical company Daiichi Sankyo of infringing patents with a recently-approved breast cancer drug.
Abbott Laboratories has asked an Illinois court to halt a former employee from using its name and trademarks to sell COVID-19 diagnostic tests.
The English High Court has concluded that Merck Sharp Dohme is not infringing a patent owned by Pfizer through the sale of its pneumococcal conjugate vaccine.
Israeli generics company Teva has withdrawn its oppositions to two patents owned by Shield Therapeutics before the European Patent Office.
Kilpatrick Townsend & Stockton has strengthened its life sciences expertise with the addition of a patent litigation team, that includes four litigators from DLA Piper.
A medical device company, St. Jude Medical, part of Abbott Laboratories, failed in its bid to invalidate a patent for an artificial heart valve at the US Court of Appeals for the Federal Circuit yesterday, Thursday, October 15.